Valuation: Myriad Genetics, Inc.

Market Cap 403M 359M 333M 302M 567M 38.18B 577M 3.99B 1.57B 19.95B 1.51B 1.48B 63.79B P/E 2026 *
-2.69x
P/E 2027 * -3.22x
Enterprise Value 354M 315M 292M 266M 498M 33.53B 506M 3.5B 1.38B 17.53B 1.33B 1.3B 56.03B EV / Sales 2026 *
0.45x
EV / Sales 2027 * 0.41x
Free-Float
95.99%
Yield 2026 *
-
Yield 2027 * -
1 day+5.78%
1 week+0.24%
Current month-2.32%
1 month+8.23%
3 months-31.88%
6 months-17.13%
Current year-31.54%
1 week 3.95
Extreme 3.95
4.42
1 month 3.76
Extreme 3.76
4.83
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.5
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
32.9
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Tax

Chief Financial Officer

-2,555 0.0027%
16/9/26 Free

Executive/Senior Manager

257,731 0.2695%
16/9/26 Other

Executive/Senior Manager

93,493 0.0977%
Change 5-day change 1-year change 3-year change Capi.($)
+5.78%+0.24%-46.03%-71.28% 381M
-0.79%+2.20%-19.04%+9.03% 181B
-2.09%+0.91%-3.14%+28.22% 116B
+1.11%+5.43%-20.43%+11.00% 113B
-1.52%+3.61%-51.34%-6.22% 79.83B
-0.27%+4.60%+4.72%+79.05% 65.06B
+0.76%+1.98%+14.30%+76.63% 54.35B
-0.53%+0.98%+0.87%-25.92% 52.23B
-0.81%+6.08%-12.53%+30.57% 44.15B
-0.07%+0.07%+29.10%-0.07% 32.47B
Average +0.17%+2.72%-10.35%+13.10% 73.9B
Weighted average by Cap. -0.56%+2.98%-11.81%+20.21%

Financials

2026 *2027 *
Net sales 778M 693M 642M 584M 1.1B 73.75B 1.11B 7.7B 3.03B 38.55B 2.92B 2.86B 123B 820M 731M 677M 616M 1.16B 77.79B 1.17B 8.13B 3.2B 40.66B 3.08B 3.01B 130B
Net income -140M -124M -115M -105M -197M -13.23B -200M -1.38B -544M -6.92B -524M -513M -22.11B -106M -94.69M -87.71M -79.75M -150M -10.07B -152M -1.05B -414M -5.26B -399M -390M -16.83B
Net Debt -48.99M -43.67M -40.45M -36.78M -69.01M -4.64B -70.15M -485M -191M -2.43B -184M -180M -7.76B -67.76M -60.4M -55.95M -50.87M -95.46M -6.42B -97.03M -671M -264M -3.36B -254M -249M -10.73B
Projected Income Statement - Annual - Myriad Genetics, Inc.
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
19/10/26 USD 4.210 +5.78% 1,355,834
16/10/26 USD 3.980 -8.51% 1,425,473
15/10/26 USD 4.350 +4.82% 1,069,861
14/10/26 USD 4.150 +1.72% 1,860,260
13/10/26 USD 4.080 -2.86% 1,379,441
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Myriad Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
4.210USD
Average target price
4.112USD
Spread / Average Target
-2.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Myriad Genetics, Inc.
  1. Stock Market
  2. Stocks
  3. MYGN Stock